Cingulate (CING) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Cingulate (CING) is Neutral.

The composite score behind that read is -0.15, weighing +0.00 of bullish evidence against -0.40 bearish.

Cingulate last closed at $4.89, +0.20% on the session.

Against the IVW growth benchmark the position is -0.60% over the forecast window.

The read is built from 11 underlying insights — 0 bullish and 11 bearish.

Agreement across those insights is 100%.

20 graded predictions for CING so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Cingulate in the 4th percentile on return on equity, where 100 is best.

Cingulate is classified under Health Care / Pharmaceuticals, with a market capitalisation of $70.96M.

StockMap tracks Cingulate as the 108th largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Cingulate ranks 93rd of 151 in the group, against a group median of -0.08.